Treatment groups were similar with regard to sex, primary tumor location, and presence of metastasis, although patients receiving combination nivolumab-ipilimumab had a lower Eastern Cooperative Oncology Group status, were younger, and were more likely to be BRAF V600E positive than those receiving anti–programmed cell death protein 1 (anti–PD-1) monotherapy. Here, BRAF is linked to neoplasm.